Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.

发布时间：2018-05-13 / 浏览次数：715 次

上一篇： In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

下一篇： Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent

返回列表